Fideuram Intesa Sanpaolo Private Banking S.P.A. Purchases 38,666 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Fideuram Intesa Sanpaolo Private Banking S.P.A. lifted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 63.0% during the 1st quarter, HoldingsChannel reports. The firm owned 99,995 shares of the biopharmaceutical company’s stock after buying an additional 38,666 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A.’s holdings in Ultragenyx Pharmaceutical were worth $2,095,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Ultragenyx Pharmaceutical by 14.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock worth $8,414,000 after buying an additional 29,984 shares in the last quarter. Creative Planning purchased a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at about $454,000. American Century Companies Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at about $366,000. M&T Bank Corp boosted its position in shares of Ultragenyx Pharmaceutical by 19.7% during the 2nd quarter. M&T Bank Corp now owns 7,232 shares of the biopharmaceutical company’s stock valued at $263,000 after acquiring an additional 1,192 shares during the last quarter. Finally, Amundi boosted its position in shares of Ultragenyx Pharmaceutical by 1,560.4% during the 2nd quarter. Amundi now owns 99,161 shares of the biopharmaceutical company’s stock valued at $3,913,000 after acquiring an additional 93,189 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Insider Activity

In other Ultragenyx Pharmaceutical news, Director Shehnaaz Suliman sold 5,740 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $25.12, for a total value of $144,188.80. Following the sale, the director owned 27,951 shares of the company’s stock, valued at $702,129.12. This trade represents a 17.04% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $25.05, for a total transaction of $50,100.00. Following the completion of the transaction, the director owned 21,095 shares in the company, valued at $528,429.75. The trade was a 8.66% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 19,319 shares of company stock worth $476,837. 5.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. The Goldman Sachs Group cut shares of Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $61.00 to $25.00 in a research report on Tuesday, March 24th. Cantor Fitzgerald lifted their target price on shares of Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the company an “overweight” rating in a research report on Thursday, May 21st. Wedbush dropped their target price on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Truist Financial raised shares of Ultragenyx Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, Guggenheim lowered their price objective on shares of Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $59.56.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE stock opened at $33.47 on Friday. The company has a market capitalization of $3.30 billion, a P/E ratio of -5.48 and a beta of 0.31. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $18.29 and a fifty-two week high of $42.37. The stock has a 50 day moving average price of $25.68 and a two-hundred day moving average price of $24.55.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The firm had revenue of $136.00 million during the quarter, compared to the consensus estimate of $158.19 million. During the same quarter in the prior year, the business posted ($1.57) EPS. The firm’s revenue for the quarter was down 2.2% on a year-over-year basis. As a group, equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -4.53 earnings per share for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.